Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation.

Kim, Paul Y; Yeh, Calvin H; Dale, Brian J; Leslie, Beverly A; Stafford, Alan R; Fredenburgh, James C; Hirsh, Jack; Weitz, Jeffrey I

Kim, Paul Y; Yeh, Calvin H; Dale, Brian J; Leslie, Beverly A; Stafford, Alan R; Fredenburgh, James C; Hirsh, Jack; Weitz, Jeffrey I.

Afiliación

Kim PY; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Yeh CH; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Dale BJ; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Leslie BA; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Stafford AR; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Fredenburgh JC; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
Hirsh J; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Weitz JI; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

TH Open ; 2(2): e190-e201, 2018 Apr.

Article en En | MEDLINE | ID: mdl-31249942

Palabras clave

DOAC; coagulation assays; coagulation inhibitors; inhibition kinetics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: TH Open Año: 2018 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google